Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (GB2) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof-of-Concept

G2B-002, the first therapeutic proof-of-concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof-of-concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of:

Rare illnesses
Pediatric patients
Oncologic diseases

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
  • Gate2Brain
  • Gate2Brain
  • Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Gate2Brain, beyond barriers. An interview by Oncobites

,
A novel technological platform for the delivery of therapeutics across biological barriers   Meritxell…
Read more

Gate2Brain honored with an award as part of the EIT Health “Wild Card” program

,
Gate2Brain has recently been honored with an award as part of the EIT Health "Wild Card" program! What…
Read more

Finalist of EIT Health Wild Card Programme 2023

,
Gate2Brain has proudly earned a spot as a finalist in the esteemed 2023 EIT Health Wild Card Programme,…
Read more
norrskengate2brain

Gate2Brain has joined Norrsken Barcelona

We’re thrilled to share the exciting news that Gate2Brain has joined Norrsken House Barcelona. Our…
Read more
BioMan4R2

Gate2Brain selected for the BioMan4R2 Eurocluster

Announcement of the 25 grant winners In April 2023, the call for applications was launched to make…
Read more
10 Top Biotech Startups to Watch in 2023StartUs

10 Top Biotech Startups to Watch in 2023

Global Startup Heat Map highlights 10 BioTech Startups to Watch in 2023 Through the Big Data & Artificial…
Read more
Gate2Brain among the 5 Catalan startups that have obtained funding from EIC Acceleratorcanva

Gate2Brain among the 5 Catalan startups that have obtained funding from EIC Accelerator

According to ACCIÓ, Catalonia is the second European region attracting the most funding for deep tech…
Read more
gate2brain finalist south summit 2023south summit

Gate2Brain finalist of the South Summit Madrid

Gate2Brain has been named a finalist in the Health Category of the South Summit Madrid 2023. The event…
Read more
Three University of Barcelona spin-offs led by women will receive funding as part of the Women TechEU pilot callFundació Bosch i Gimpera

Three University of Barcelona spin-offs will receive funding from Women TechEU pilot call

THREE UNIVERSITY OF BARCELONA SPIN-OFFS LED BY WOMEN WILL RECEIVE FUNDING AS PART OF THE WOMEN TechEU…
Read more
NEWS MEDIA
1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social